Addex Therapeutics partner discontinues development of ADX71149

Addex Therapeutics announced that its partner Janssen Pharmaceuticals (JNJ) has informed the company that it has discontinued development of ADX71149 in epilepsy. The partnership between the two companies remains ongoing while the full data set from the Phase 2 study of ADX71149 as an adjunctive epilepsy treatment is analyzed. The decision follows top-line Phase 2 data announced on April 29, showing that adjunctive ADX71149 administration in patients with focal onset seizures with suboptimal response to levetiracetam or brivaracetam did not achieve statistical significance for the primary endpoint of time for patients to reach baseline seizure count when ADX71149 was added to standard of care.